Thiazolidinediones

Troglitazone
Rosiglitazone Indications: type 2 diabetes mellitus.

Mechanism

Increases sensitivity to insulin in muscle and adipose tissue; inhibits hepatic gluconeogenesis. Binds to PPARγ (peroxisome proliferator-activated receptor gamma). Enhances effect of circulating insulin.

Comparison

Troglitazone was withdrawn from the market because of rare idiosyncratic hepatocellular toxicity. Rosiglitazone: dose related reduction in Hb and WBC (increased plasma volume?). Possibly hepatotoxic. Oedema. LFT monitoring recommended because of Troglitazone.

Adverse effects

Does NOT produce hypoglycaemia.